There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report), Adverum Biotechnologies (ADVM – Research Report) and Alignment Healthcare (ALHC – Research Report) with bullish sentiments.
Sarepta Therapeutics (SRPT)
In a report issued on November 6, Uy Ear from Mizuho Securities maintained a Buy rating on Sarepta Therapeutics, with a price target of $160.00. The company’s shares closed last Tuesday at $82.93.
According to TipRanks.com, Ear is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $121.45 average price target, representing a 50.6% upside. In a report issued on October 31, J.P. Morgan also maintained a Buy rating on the stock with a $115.00 price target.
See the top stocks recommended by analysts >>
Adverum Biotechnologies (ADVM)
Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Adverum Biotechnologies on November 6 and set a price target of $2.00. The company’s shares closed last Tuesday at $0.91.
According to TipRanks.com, Suvannavejh ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Adverum Biotechnologies with a $3.75 average price target.
Alignment Healthcare (ALHC)
Leerink Partners analyst Whit Mayo reiterated a Buy rating on Alignment Healthcare on November 3 and set a price target of $9.00. The company’s shares closed last Tuesday at $6.18, close to its 52-week low of $4.88.
According to TipRanks.com, Mayo is a 3-star analyst with an average return of
Alignment Healthcare has an analyst consensus of Moderate Buy, with a price target consensus of $8.65, which is a 48.9% upside from current levels. In a report issued on November 3, Goldman Sachs also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SRPT:
